Novuson Reports Direct Therapeutic Ultrasound Improving Surgical Safety and Precision

Summation

  •   Investors will hold partial ownership in Novuson and will have the opportunity to profit if and when Novuson does well.
  • “We at Novuson believe the Ultrastat 3mm MiniLS vessel sealer/divider will disrupt the surgical market, improving patient safety with DTU precision.
  • Novuson is focused on finishing validation studies for the regulatory clearance of our first-in-class Ultrastat 3mm MiniLS advanced energy sealer/divider.

Novuson announces the recent launch of their Regulation Crowdfunding raise. Join us in improving surgical safety and precision.

Novuson is focused on finishing validation studies for the regulatory clearance of our first-in-class Ultrastat 3mm MiniLS advanced energy sealer/divider. Energy based surgical instruments are used in most surgical procedures. They improve surgical efficiency.

We intend to revolutionize surgical safety and precision,” said Founder and CEO, Dr. Stuart Mitchell. “We at Novuson believe the Ultrastat 3mm MiniLS vessel sealer/divider will disrupt the surgical market, improving patient safety with DTU precision.”

With the help of StartEngine, we are excited to announce the commencement of our equity crowdfunding campaign. Equity crowdfunding allows companies like Novuson to raise capital from the public.  Investors will hold partial ownership in Novuson and will have the opportunity to profit if and when Novuson does well.

More information here.

More News

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models

AbbVie and Gilgamesh Pharmaceuticals | Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

Under terms of the agreement, AbbVie and Gilgamesh Pharmaceuticals have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders.

PharmaLogic Announces Opening of Radiopharmaceutical Production Facility in New York City

Acquired in 2022, the facility has undergone extensive renovations and boasts state-of-the-art equipment, signifying the companys significant investment in fostering the development of novel radiopharmaceuticals in the region.

By using this website you agree to accept Medical Device News Magazine Privacy Policy